Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed / Refractory Cancer Indications

Multiple Myeloma

This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in patients with relapsed / refractory multiple myeloma (MM), colorectal cancer (CRC), metastatic castration resistant prostate cancer (mCRPC), and higher risk myelodysplastic syndrome (MDS). Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results. This study is currently closed for enrollment for patients with relapsed / refractory multiple myeloma (MM) or colorectal cancer (CRC).
Multiple Myeloma
I/II
Cornell, Robert
NCT02649790
VICCHEM15112

Olaparib with and without AZD1775, AZD5363, and AZD2014 in Treating Patients with Advanced Solid Tumors

Miscellaneous

This phase II trial studies how well olaparib works with and without other targeted therapies in treating patients with solid tumors that have spread to other places in the body. Olaparib, WEE1 inhibitor AZD1775 (AZD1775), Akt serine / threonine-specific protein kinase (Akt) inhibitor AZD5363 (AZD5363), and mammalian target of rapamycin (mTor) kinase inhibitor AZD2014 (AZD2014) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and repair. It is not yet known if giving olaparib alone or in combination with AZD1775, AZD5363, or AZD2014 will work better in treating patients with solid tumors that have spread to other places in the body.
Miscellaneous
II
Keedy, Vicki
NCT02576444
VICCMD1672

Nivolumab with or without Tadalafil in Treating Patients with Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Head/Neck

This randomized pilot early phase I trial studies how well nivolumab with or without tadalafil work in treating patients with head and neck squamous cell carcinoma that has come back and can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Tadalafil may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and tadalafil may work better in treating patients head and neck squamous cell carcinoma.
Head/Neck
Pilot
Kim, Young Jun
NCT03238365
VICCHN1794

Pevonedistat and Azacitidine in Treating Patients with Refractory or Relapsed Myelodysplastic Syndrome or Myelodysplastic Syndrome / Myeloproliferative Neoplasm Who Fail Primary Therapy

Myelodysplastic Syndrome

This phase II trial studies how well pevonedistat and azacitidine work in treating patients with myelodysplastic syndrome or myelodysplastic syndrome / myeloproliferative neoplasm that have fails primary therapy and that does not respond to treatment or has come back. Pevonedistat and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Myelodysplastic Syndrome
II
Savona, Michael
NCT03238248
VICCHEM16146

M3541 in Combination With Radiotherapy in Subjects With Solid Tumors

Multiple Cancer Types

This dose-escalation study will evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and signs of clinical efficacy of M3541 in combination with fractionated palliative radiotherapy (RT) in subjects with solid tumors with malignant lesions in the thorax, abdominal cavity, head and neck region, or extremities likely to benefit from palliative RT.
Esophageal, Gastric/Gastroesophageal, Gastrointestinal, Head/Neck, Lung, Miscellaneous, Phase I
I
Berlin, Jordan
NCT03225105
VICCPHI1748

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Lymphoma

Patients with high tumor burden, low grade follicular lymphoma that has never been treated, will receive venetoclax in combination with obinutuzumab and bendamustine. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma. Venetoclax may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding venetoclax to obinutuzumab and bendamustine improves the response (the tumor shrinks or disappears) in patients with follicular lymphoma.
Lymphoma
II
Reddy, Nishitha
NCT03113422
VICCPCL17100

Study of GBR 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.
Multiple Myeloma
I
Cornell, Robert
NCT03309111
VICCHEMP17111

Trametinib in Treating Patients with Advanced Melanoma with BRAF Non-V600 Mutations

Melanoma

This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Melanoma
II
Johnson, Douglas
NCT02296112
VICCMEL1457

A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed / Refractory Diffuse Large B Cell Lymphoma

Lymphoma

The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed / refractory DLBCL.
Lymphoma
III
Oluwole, Olalekan
NCT03391466
VICCBMT17102

Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia

Multiple Cancer Types

This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
Leukemia, Pediatric Leukemia
III
Friedman, Debra
NCT02101853
COGAALL1331

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: